AlerGenetica is a pre-clinical stage biopharma company which is investigating the possibility of a vaccine for fungal allergies.
We intend to develop solutions to improve the health of fungal allergy affected patients. According to The World Health Organization (WHO), allergies are the fourth most important disease in the world estimating that by 2010 between 40-50% of the world’s population could be affected. A substantial portion of this population (10-30%) will be allergic to filamentous fungi present in the environment with patients suffering from allergic rhinitis to more severe cases of asthma.
Using rapid advances in the fields of immunology, fungal genomics, bioinformatics and protein chemistry, we are developing an innovative platform of protein-based technologies to treat specific allergenic diseases.